| 货号 | 10006967-10mg |
| 描述 | There is substantial evidence that the cysteinyl leukotrienes (CysLTs), such as LTC4, LTD4, and LTE4, play an important role in the pathophysiology of asthma.1,2 Arachidonic acid is the precursor fatty acid that is transformed into LTs by way of the 5-lipoxygenase (5-LO) pathway. Zileuton (Zyflo™) is a reversible 5-LO inhibitor that was approved in 1997 for the prevention and treatment of asthma in the USA, but was withdrawn by Abbott Laboratories in 2003.3,4 Zileuton inhibits 5-LO from rat basophilic leukemia-1 (RBL-1) cells with an IC50 value of 0.5 µM. It is a potent inhibitor of leukotriene B4 production in purified human peripheral blood polymorphonuclear leukocytes (PMNL) with an IC50 value of 0.6 µM.3 |
| 别名 | Zyflo™; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Drazen, J.M.,Israel, E., and OByrne, P.M. Treatment of asthma with drugs modifying the leukotriene pathway. New England Journal of Medicine 340, 197-206 (1999). 2.Centanni, S., and Santus, P. Antileukotrienes in clinical development for asthma. Expert Opinion on Investigational Drugs 11(1), 49-58 (2002). 3.Carter, G.W.,Young, P.R.,Albert, D.H., et al. 5-Lipoxygenase inhibitory activity of zileuton. Journal of Pharmacology and Experimental Therapeutics 256, 929-937 (1991). 4.Zouboulis, C.C.,Saborowski, A., and Boschnakow, A. Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. Dermatology 210, 36-38 (2005). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | >98% |
| 计算分子量 | 236.3 |
| 分子式 | C11H12N2O2S |
| CAS号 | 111406-87-2 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |